Recent Press Releases

Latifah Hospital and Bayer HealthCare Organize Endometriosis Awareness Campaign

Latifah Hospital and Bayer HealthCare Organize Endometriosis Awareness Campaign Over 100,000 Women in UAE suffer from Endometriosis Disease Dubai, 10 March 2013 - Given the global increase for the...

Teva Announces Launch of Generic Xeloda® Tablets 150 MG and 500 MG in the United States

Teva Announces Launch of Generic Xeloda® Tablets 150 MG and 500 MG in the United States JERUSALEM--(BUSINESS WIRE)--Mar. 7, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the...

PRAC recommends product information of zolpidem be updated with new advice to minimise the risk of next-morning impaired driving ability and mental alertness

PRAC recommends product information of zolpidem be updated with new advice to minimise the risk of next-morning impaired driving ability and mental alertness The European Medicines Agency's...

Bristol-Myers Squibb to close manufacturing facility in Cruiserath, Co. Ireland

Bristol-Myers Squibb to close manufacturing facility in Cruiserath, Co. Ireland March 6, 2014 -- Bristol-Myers Squibb will close its manufacturing facility in Cruiserath, Co. Dublin by the end of...

Pfizer Initiates Nationwide Voluntary Recall of Two Lots of Pfizer's Effexor XR® 150 Mg Extended-Release Capsules and One Lot of Greenstone's Venlafaxine HCl 150 Mg Extended-Release Capsules Due to the Possible Presence of Tikosyn® Capsules

Recall -- Firm Press Release Pfizer Initiates Nationwide Voluntary Recall of Two Lots of Pfizer's Effexor XR® 150 Mg Extended-Release Capsules and One Lot of Greenstone's Venlafaxine HCl...

Novartis announces Xolair(R) approved in EU as first and only licensed therapy for chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines

Novartis announces Xolair(R) approved in EU as first and only licensed therapy for chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines (Thomson Reuters ONE via COMTEX) --...

U.S. FDA Approves AVEED™ (Testosterone Undecanoate) Injectable Testosterone Replacement Therapy For Men Living With Hypogonadism, Or Low-T

U.S. FDA Approves AVEED™ (Testosterone Undecanoate) Injectable Testosterone Replacement Therapy For Men Living With Hypogonadism, Or Low-T AVEED offers distinct dosing schedule to increase...

Award-Winning Singer And Actress, Kristin Chenoweth, Reveals Her Journey With Asthma And Urges Others To Get Serious About Asthma Safety

National Campaign Seeks to Educate People with Asthma on the Importance of 'Knowing Their Count'

LANDOVER, Md.,

Lilly to Participate in Barclays Healthcare Conference

INDIANAPOLIS, March 5, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Barclays Global

Amgen Announces 2014 Second Quarter Dividend

THOUSAND OAKS, Calif., March 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Dir

U.S. Food and Drug Administration Issues Complete Response Letter for Empagliflozin

Boehringer Ingelheim and Lilly are committed to working with the FDA

RIDGEFIELD, Conn. and INDIANAPOLIS<

International Panel of Pathology Leaders Develop Principles for Patient Safety

TUCSON, Ariz., March 5, 2014 /PRNewswire/ -- An international panel of leaders in the pathology community tod

U.S. Food and Drug Administration Issues Complete Response Letter for Empagliflozin

Boehringer Ingelheim and Lilly are committed to working with the FDA RIDGEFIELD, Conn. and INDIANAPOLIS, March 5, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly...

Forest Laboratories and Adamas Pharmaceuticals Announce Forest's Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimer's Disease

Forest Laboratories and Adamas Pharmaceuticals Announce Forest's Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimer's Disease...

Alexza Announces the U.S. Commercial Launch of ADASUVE® by Teva Pharmaceuticals

ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults

Public Citizen Expert to Tell Lawmakers That Changes to Generic Drug Labeling Are Needed, Won't Increase Costs

Feb. 28, 2014 Public Citizen Expert to Tell Lawmakers That Changes to Generic Drug Labeling Are Needed, Won't Increase Costs Subcommittee Hearing Monday to Examine FDA's Proposed Changes to...

GPhA to Congress: FDA Proposed Rule on Labeling Risks Widespread Confusion, Undermines Hatch-Waxman

GPhA to Congress: FDA Proposed Rule on Labeling Risks Widespread Confusion, Undermines Hatch-Waxman Current Approach Creates Patient Safety Risks, Adds $4 Billion in Annual Health Costs, Experts Say...

Actavis Confirms Generic Multaq® Patent Challenge

Actavis Confirms Generic Multaq® Patent Challenge Date(s): Feb. 28, 2014 8:00 AM DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New...

Teva Launches ADASUVE® in U.S.

Teva Launches ADASUVE® in U.S. The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults Date(s): 3-Mar-2014...

Actavis Confirms Generic Colcrys® Patent Challenge

Actavis Confirms Generic Colcrys® Patent Challenge Date(s): Feb. 28, 2014 4:05 PM DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated...